GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Ending Cash Position : ₦0 Mil (As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is GlaxoSmithKline Consumer Nigeria Ending Cash Position?

GlaxoSmithKline Consumer Nigeria's Ending Cash Position for the quarter that ended in Jun. 2023 was ₦0 Mil.

GlaxoSmithKline Consumer Nigeria's quarterly Ending Cash Position increased from Sep. 2022 (₦18,196 Mil) to Dec. 2022 (₦19,976 Mil) but then declined from Dec. 2022 (₦19,976 Mil) to Jun. 2023 (₦0 Mil).

GlaxoSmithKline Consumer Nigeria's annual Ending Cash Position declined from Dec. 2020 (₦12,886 Mil) to Dec. 2021 (₦12,747 Mil) but then increased from Dec. 2021 (₦12,747 Mil) to Dec. 2022 (₦19,976 Mil).

GlaxoSmithKline Consumer Nigeria Ending Cash Position Historical Data

The historical data trend for GlaxoSmithKline Consumer Nigeria's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Consumer Nigeria Ending Cash Position Chart

GlaxoSmithKline Consumer Nigeria Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Ending Cash Position

Get a 7-Day Free Trial

3,388.94

3,710.81

12,885.58

12,746.57

19,976.02

GlaxoSmithKline Consumer Nigeria Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23
Ending Cash Position	Get a 7-Day Free Trial															11,289.24	12,877.54	18,196.35	19,976.02	-

GlaxoSmithKline Consumer Nigeria Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GlaxoSmithKline Consumer Nigeria's Ending Cash Position for the fiscal year that ended in Dec. 2022 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	12746.57	+	7229.453
	=	19,976

GlaxoSmithKline Consumer Nigeria's Ending Cash Position for the quarter that ended in Jun. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	0	+	0
	=	0

GlaxoSmithKline Consumer Nigeria Ending Cash Position Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Consumer Nigeria's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Consumer Nigeria PLC (NSA:GLAXOSMITH) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Industrial Avenue, Ilupeju, P.M.B. 21218, Ikeja, GSK House, Lagos, NGA

Website

https://www.ng.gsk.com

GlaxoSmithKline Consumer Nigeria PLC is a healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. The company has two reportable segments, the Consumer Healthcare segment consisting of oral care, over-the-counter (OTC) medicines, and nutritional healthcare; and the Pharmaceuticals segment consisting of vaccines and prescription drugs. The company's product line includes panadol, Andrews liver salt, Macleans, ampiclox, Sensodyne, and others. The generates maximum revenue from the Pharmaceuticals segment.

GlaxoSmithKline Consumer Nigeria (NSA:GLAXOSMITH) Headlines

No Headlines